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No total, existiam 11 doentes com trissomia 8 
isolada, um valor ligeiramente inferior ao descrito na 
literatura. 
conclusão
A ocorrência de trissomia 8 em diferentes tipos de 
leucemias está descrita na literatura, e a sua importância 
está também para além do estabelecimento dos grupos 
de risco, no facto de cerca de 25% dos doentes com 
síndrome mielodisplásico com trissomia 8 estarem 
em risco de desenvolver leucemia. Para este estudo 
as percentagens dos doentes com trissomia 8 são 
ligeiramente inferiores às descritas na literatura. 
Provavelmente utilizando as técnicas de FISH, uma 
técnica mais sensível, poderemos obter valores mais 
próximos dos descritos. 
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intRoduction
Acquired AmpC beta-lactamases (qAmpC) which 
confer resistance to cephamycins and reduced 
susceptibility to extended-spectrum cephalosporins 
and β-lactamase inhibitors have increasingly been 
recognized as an emerging problem worldwide. 
qAmpCs enzymes are grouped according to the DNA 
sequence similarity with natural chromosomal AmpCs 
of some Enterobacteriaceae species, namely C. 
freundii (CMY-2-like, LAT-1, CFE-1), Enterobacter 
spp. (ACT-1-like, MIR-1-like), M. morgannii (DHA-
1-like) and H. alvei (ACC-1-like), and with Aeromonas 
spp. (CMY-1-like, FOX-1-like, MOX-1-like). Isolates 
harbouring qAmpCs are usually multir-resistant, and 
inappropriate empirical therapy is associated with 
high mortality ratios in invasive infections. 
objectives
Estimate the worldwide prevalence and distribution of 
qAmpC types. 
methods
We conducted a literature review on pertinent articles 
published between 2000 and 2011 on qAmpC detection 
and prevalence in Enterobacteriaceae lacking 
inducible AmpC [E. coli (EC), K. pneumoniae (KP), 
K. oxytoca (KO), P. mirabilis (PM) and Salmonella 
spp. (SM)] isolated from human infections. Estimated 
relative frequencies were calculated for qAmpC types 
detected in each country with relevant articles.
Results
A total of 26 relevant studies from 21 countries on 
qAmpC epidemiology were retrieved, comprising 
216648 isolates (182573 EC, 18858 KP, 8117 SM, 
2340 PM, and 2278 KO). qAmpCs were detected in all 
but one study from Brazil, being the worldwide overall 
prevalence 0.55% (1194/216648, or 5.5 qAmpC 
producers per 1000 isolates). Countries with higher 
prevalence were China (4%), South Korea (3.5%), 
Portugal (3%) and Poland (3%), and the lowest were 
observed in Brazil (0%), Japan (0.08%), Switzerland 
(0.16%) and Belgium (0.16%). The overall species 
specific prevalence was 4.1%, 3.5%, 1.4%, 0.5% and 
0.2% in SM, PM, KP, KO, and EC respectively. China 
presented the higher prevalence for KP (7%) and KO 
(3%), Thailand for EC (2%), while for PM and SM it 
was Poland (20.5%) and Mexico (7.7%), respectively. 
Globally, the main qAmpC variants detected were 
CMY-2 (53.1%), DHA-1 (30.6%) and CMY-2-like 
(11.7%). CMY-2 was predominantly present in EC, 
PM and SM isolates while DHA-1 was detected 
mostly among KP and KO. In countries like South 
Korea, China, and Portugal DHA-1 is the dominant 
variant, while in North America, Norway, Danmark, 
Tailand, Japan, Algeria and Spain is CMY-2.
conclusion
Although qAmpC prevalence is globally low, the results 
suggest that it is rising. This study also demonstrates 
that CMY-2 is the most prevalent qAmpC followed by 
DHA-1. Future studies are needed in order to monitor 
the spread of this emerging resistance mechanism.  
